

Potter  
Anderson  
& Corroon LLP

1313 North Market Street  
P.O. Box 951  
Wilmington, DE 19899-0951  
302 984 6000  
[www.potteranderson.com](http://www.potteranderson.com)

**Philip A. Rovner**  
Partner  
[provner@potteranderson.com](mailto:provner@potteranderson.com)  
302 984-6140 Direct Phone  
302 658-1192 Fax

December 22, 2006

**BY E-FILE**

Dr. Peter T. Dalleo  
Clerk  
U.S. District Court for the District of Delaware  
U.S. Courthouse  
844 N. King Street  
Wilmington, DE 19801

Re: Talecris Biotherapeutics, Inc. v. Baxter International Inc. and Baxter Healthcare Corporation, D. Del., C.A. No. 05-349-GMS

Dear Dr. Dalleo:

We represent Baxter International Inc. and Baxter Healthcare Corporation (“Baxter”) in the above-referenced matter. On November 1, 2006, in connection with its motion for leave to file amended answer and counterclaim (D.I. 165), Baxter submitted the Declaration of Brian T. Clarke (the “Clarke Declaration”) (D.I. 167). It recently came to our attention that two exhibits, referenced in paragraphs 12 and 13 of the Clarke Declaration, were misidentified. As a result, we have filed and served a corrected version of the Clarke Declaration and included therein corrected copies of Exhibits 9 and 10 (identified in paragraphs 12 and 13 of the Clarke Declaration). The two changes are listed below:

Paragraph 12 is revised to read:

12. A true and correct copy of TAL018558 is attached hereto as Exhibit 9.

Paragraph 13 is revised to read:

13. A true and correct copy of TAL018537-TAL018564 is attached hereto as Exhibit 10.

Dr. Peter T. Dalleo  
December 22, 2006  
Page 2

Respectfully,

/s/ Philip A. Rovner

Philip A. Rovner  
[provner@potteranderson.com](mailto:provner@potteranderson.com)

PAR/mes/769223

Enc.

cc: Jeffrey B. Bove (by E-mail and hand delivery)  
Bradford J. Badke (by E-mail and Federal Express)